Evidence map›Paper›PMID 29572239›Full record

ReviewCold Spring Harbor molecular case studies2018

Identification of novel

James A Connelly, Rajen J Mody, Yi-Mi Wu, Dan R Robinson, Robert J Lonigro, Pankaj Vats, Erica Rabban, Bailey Anderson, Kelly Walkovich

Open access · diamondAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cold Spring Harbor molecular case studies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Diagnosis and therapeutic decision-making for the neutropenic patient.Hematology. American Society of Hematology. Education Program · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

James A ConnellyDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6310, USA.ORCID 0000-0001-7223-375X
Rajen J ModyDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Robert J LonigroMichigan Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Pankaj VatsMichigan Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Erica RabbanMichigan Center for Translational Pathology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Bailey AndersonDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Kelly WalkovichDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
University of Michigan · USVanderbilt University Medical Center · US

Funding

Sequencing, Analysis, and Interpretation of SequencingUM1HG006508 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, PIENTA, KENNETH J. · 2013 to 2016
$7.8M
NHGRI NIH HHS UM1 HG006508
6 · The paper itself

Abstract

Severe congenital neutropenia (SCN) is a rare hematologic disorder characterized by defective myelopoiesis and a high incidence of malignant transformation to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). SCN patients who develop MDS/AML have excessive toxicities to traditional chemotherapy, and safer therapies are needed to improve overall survival in this population. In this report, we outline the use of a prospective integrative clinical sequencing trial (PEDS-MIONCOSEQ) in a patient with SCN and AML to help identify oncogenic targets for less toxic agents. Integrative sequencing identified two somatic

Indexed as

AdolescentAllelesBiomarkersBiopsyBone MarrowCongenital Bone Marrow Failure SyndromesExome SequencingGene Expression ProfilingGenotypeHumansIn Situ Hybridization, FluorescenceKaryotypeLeukemia, Myeloid, AcuteMaleMDS1 and EVI1 Complex Locus ProteinNeoplasms, Second PrimaryBiomarkersMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanOncogene Proteins, Fusionacute myeloid leukemiacongenital neutropenia

Identifiers

PMID29572239
PMCPMC5880254
OpenAlexW2789994308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.